Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues

被引:35
|
作者
Hosokawa, Yuko [1 ,2 ,3 ]
Masaki, Noritaka [2 ,3 ]
Takei, Shiro [2 ,3 ]
Horikawa, Makoto [2 ,3 ]
Matsushita, Shoko [2 ,3 ]
Sugiyama, Eiji [2 ,3 ]
Ogura, Hiroyuki [1 ]
Shiiya, Norihiko [1 ]
Setou, Mitsutoshi [2 ,3 ,4 ,5 ,6 ]
机构
[1] Hamamatsu Univ, Sch Med, Dept Surg 1, Higashi Ku, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ, Sch Med, Int Mass Imaging Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ, Sch Med, Dept Cellular & Mol Anat, Higashi Ku, Hamamatsu, Shizuoka, Japan
[4] Preeminent Med Photon Educ & Res Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[5] Univ Hong Kong, Dept Anat, 6-F,William MW Mong Block,Sassoon Rd, Pokfulam, Hong Kong, Peoples R China
[6] RIKEN, Ctr Mol Imaging Sci, Chuo Ku, Kobe, Hyogo, Japan
来源
PLOS ONE | 2017年 / 12卷 / 08期
关键词
MASS-SPECTROMETRY; SURVIVAL;
D O I
10.1371/journal.pone.0183724
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Triple-negative breast cancer (TNBC) is one of the breast cancer subtype that displays a high risk of early recurrence and short overall survival. Improvement of the prognosis of patients with TNBC requires identifying a predictive factor of recurrence, which would make it possible to provide beneficial personalized treatment. However, no clinically reliable predictive factor is currently known. In this study, we investigated the predictive factor of recurrence in TNBC using matrix-assisted laser desorption/ionization-imaging mass spectrometry for lipid profiling of breast cancer specimens obtained from three and six patients with recurrent and non-recurrent TNBC, respectively. The signal for phosphatidylcholine (PC) (32:1) at m/z 732.5 was significantly higher in the recurrence group compared to the non-recurrence group (P = 0.024). PC (32:1) was more abundant in the cancer epithelial area than it was in the surrounding stroma, suggesting that abnormal lipid metabolism was associated with malignant transformation. Our results indicate PC (32:1) as a candidate predictive factor of TNBC recurrence. A future prospective study investigating whether personalized therapy based on PC (32:1) intensity improves the prognosis of patients with TNBC is recommended.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
    Kumar, Sunny
    Chatterjee, Mouli
    Ghosh, Pratyasha
    Ganguly, Kirat K.
    Basu, Malini
    Ghosh, Mrinal K.
    GENES & DISEASES, 2023, 10 (04) : 1318 - 1350
  • [32] Parallel Analyses by Mass Spectrometry (MS) and Reverse Phase Protein Array (RPPA) Reveal Complementary Proteomic Profiles in Triple-Negative Breast Cancer (TNBC) Patient Tissues and Cell Cultures
    Wang, Nan
    Zhu, Yiying
    Wang, Lianshui
    Dai, Wenshuang
    Hu, Taobo
    Song, Zhentao
    Li, Xia
    Zhang, Qi
    Ma, Jianfei
    Xia, Qianghua
    Li, Jin
    Liu, Yiqiang
    Long, Mengping
    Ding, Zhiyong
    PROTEOMICS, 2025, 25 (04)
  • [33] CK14, FOXA1, and androgen receptor (AR) expression in patients (pts) with triple-negative breast cancer (TNBC)
    Gucalp, Ayca
    Krasne, Margaret D.
    Jakate, Kiran A.
    Drill, Esther N.
    Wen, Yong Hannah
    Akram, Muzaffar
    Ho, Alice Y.
    Gupta, Gaorav P.
    Brogi, Edi
    Hudis, Clifford A.
    Traina, Tiffany A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Molecular profiling comparison of BRCA1/2-mutated and BRCA1/2 non-mutated triple-negative breast cancer (TNBC)
    Arguello, D.
    Abbott, B.
    Reddy, S.
    Gatalica, Z.
    Obeid, E.
    Goldstein, L.
    CANCER RESEARCH, 2016, 76
  • [35] RETRACTION: Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research
    Wang, Li
    Liu, Dequan
    Wu, Xingrao
    Zeng, Yueqin
    Li, Lan
    Hou, Yu
    Li, Wenhui
    Liu, Zhijie
    JOURNAL OF CELLULAR PHYSIOLOGY, 2024, 239 (11)
  • [36] A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).
    Cristea, Mihaela C.
    Frankel, Paul Henry
    Synold, Timothy W.
    Mortimer, Joanne E.
    Stewart, Daphne B.
    Wang, Edward Wenge
    Jung, Alex
    Wilczynski, Sharon P.
    Konecny, Gottfried E.
    Parungao, Dia
    Eng, Melissa
    Kilpatrick, Lindsay
    Chen, Yi-Jen
    Glaser, Scott
    Han, Ernest Soyoung
    Dellinger, Thanh Hue
    Hakim, Amy
    Lee, Stephen
    Morgan, Robert
    Wakabayashi, Mark Tsuneo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
    Bastien, E.
    Grandal, B.
    Sanchez, R.
    Ramtohul, T.
    Loirat, D.
    Sablin, M. P.
    Vincent-Salomon, A.
    Pierga, J-Y.
    Bidard, F. C.
    Malhaire, C.
    Savignoni, A.
    Romano, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S347 - S348
  • [38] Founder effect and a high prevalence of BRCA1 mutations among young Mexican triple-negative breast cancer (TNBC) patients.
    Mayte Villarreal-Garza, Cynthia
    Weitzel, Jeffrey N.
    Sifuentes, Erika
    Llacuachaqui, Marcia
    Herzog, Josef
    Castillo, Danielle
    Royer, Rob
    Cristina Magallanes-Hoyos, Maria
    Maria Alvarez-Gomez, Rosa
    Gallardo, Lenny
    Lara-Medina, Fernando
    Herrera, Luis Alonso
    Narod, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Association of BRCA1 promoter methylation in triple-negative breast cancer (TNBC) with resistance to standard anthracyline-based adjuvant chemotherapy
    Sharma, P.
    Kimler, B. F.
    Park, Y. A.
    Stecklein, S. R.
    Khan, Q. J.
    Petroff, B. K.
    Tawfik, O. W.
    Jensen, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
    Emens, Leisha A.
    Braiteh, Fadi S.
    Cassier, Philippe
    Delord, Jean-Pierre
    Eder, Joseph Paul
    Fasso, Marcella
    Xiao, Yuanyuan
    Wang, Yan
    Molinere, Luciana
    Chen, Daniel S.
    Krop, Ian
    CANCER RESEARCH, 2015, 75